News topic
Industry News & Updates
Pharmaceutical company pipeline, supply chain, pricing, and commercial developments in the peptide market.
5 articles in this topic
Semaglutide Could Cost $3/Month: Patent Expiry and Generic Timeline
Analysis shows generic semaglutide could be produced for $3/month. With patents expiring in 8 countries in 2026, the cost landscape for Ozempic and Wegovy is about to change dramatically.
2026 Weight Loss Drug Pipeline: What Comes After Ozempic
Retatrutide, orforglipron, CagriSema, and more — the next wave of obesity drugs promises even greater weight loss, oral delivery, and new mechanisms. Here is the full pipeline.
How GLP-1 Drugs Are Cutting America's Grocery Bills
A Cornell study found households on GLP-1 drugs cut grocery spending by over 5% within 6 months, with even bigger drops at fast-food restaurants. The food industry is taking notice.
Novo Nordisk Slashes GLP-1 Prices 70%: What It Means for Patients
Novo Nordisk announced up to 70% price cuts on its GLP-1 medications in early 2026. We analyze what this actually means for patient out-of-pocket costs.
Peptides Go Mainstream: NPR, MIT Tech Review, and PolitiFact Cover the Trend
In a single week in February 2026, NPR, MIT Technology Review, and PolitiFact all published major pieces on the peptide trend. We analyze their coverage.